Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Paricalcitol
Drug ID BADD_D01676
Description Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Indications and Usage For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
Marketing Status Prescription; Discontinued
ATC Code H05BX02
DrugBank ID DB00910
KEGG ID D00930
MeSH ID C084656
PubChem ID 5281104
TTD Drug ID D0N1TP
NDC Product Code 25000-012; 70121-1036; 65862-938; 68382-331; 68513-1054; 25000-014; 66499-0019; 0409-1008; 63629-2452; 69452-145; 17478-033; 25000-017; 10888-8103; 0143-9625; 67457-692; 70121-1035; 49483-687; 43598-563; 55150-213; 48943-0033; 58032-1001; 55111-663; 70121-1034; 69452-146; 65862-937; 55150-214; 68382-330; 0143-9624; 11014-0053; 43598-564; 43598-565; 43598-562; 0074-9036; 55111-665; 63629-2453; 0074-1658; 55150-212; 10888-8102; 55150-215; 65162-822; 58272-192; 49483-689; 0409-1007; 65162-824; 49483-688; 65162-823; 55111-664; 69452-147; 11014-0048; 16729-310; 0074-9037; 16729-311; 70121-1033; 67457-380; 65862-936; 10888-8104; 0143-9596; 0074-4637; 14474-021
Synonyms paricalcitol | 19-nor-1alpha,25-dihydroxyvitamin D2 | 19-nor-1,25-(OH)2D2 | Zemplar | paricalcitol-d6
Chemical Information
Molecular Formula C27H44O3
CAS Registry Number 131918-61-1
SMILES CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionParathyroid hormone/parathyroid hormone-related peptide receptorQ03431T6771011576883; 9697664; 9808143
Adverse drug reactionAlkaline phosphatase, placental typeP05187Not Available11576883; 9697664; 9808143
Electrolyte imbalanceGastrin/cholecystokinin type B receptorP32239T0584912529809; 12073167; 9160584; 7619662
Iron and trace metal metabolism disordersParathyroid hormone/parathyroid hormone-related peptide receptorQ03431T6771011576883; 9697664; 9808143
Iron and trace metal metabolism disordersAlkaline phosphatase, placental typeP05187Not Available11576883; 9697664; 9808143
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bleeding time prolonged13.01.02.002--Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood calcium increased13.11.01.0030.008993%Not Available
Blood creatinine increased13.13.01.004--
Blood parathyroid hormone increased13.10.07.0020.026979%Not Available
Blood pressure decreased13.14.03.002--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood urea increased13.13.01.006--Not Available
Body temperature increased13.15.01.001--Not Available
Bone pain15.02.01.001--
Bradycardia02.03.02.002--Not Available
Breast cancer16.10.01.001; 21.05.01.003--Not Available
Breast pain21.05.05.003--
Breast tenderness21.05.05.004--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Calcinosis08.03.04.002--Not Available
Cardiac arrest02.03.04.0010.087974%
Cardiac failure02.05.01.0010.218175%
Cardiac failure congestive02.05.01.002--Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.172429%Not Available
Cardiogenic shock24.06.02.006; 02.05.01.003--Not Available
Cardiovascular disorder24.03.02.009; 02.01.01.0010.164218%Not Available
Cellulitis23.09.01.001; 11.02.01.001--Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
Cerebral ischaemia24.04.06.003; 17.08.01.0050.004692%
Cerebrovascular accident24.03.05.001; 17.08.01.0070.160699%
Cerebrovascular disorder24.03.05.002; 17.08.02.0020.053957%Not Available
Cervix carcinoma21.06.02.001; 16.12.01.0010.002346%Not Available
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.009--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 12 Pages